Claim OwnershipCME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Subscribed: 10Played: 35
Subscribe
© 2022
Description
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Rheumatology, Immunology, and Infectious Diseases by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions from rheumatology, immunology, and infectious diseases. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
55 Episodes
Reverse
Please visit answersincme.com/860/95719487-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in vaccine-preventable diseases discuss the most up-to-date evidence-based recommendations for flu vaccination, as well as strategies to enhance uptake across all age groups. Upon completion of this activity, participants should be better able to: Discuss the therapeutic rationale for seasonal influenza vaccination across all age groups; Describe the clinical profiles of recommended influenza vaccines; and Outline practical strategies to enhance influenza vaccination uptake across all age groups.
Please visit answersincme.com/ZXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in interstitial lung disease (ILD) discuss the latest information, including post-congress insights, on advancing patient-centered ILD care with antifibrotics, treatment innovations, and multidisciplinary approaches. Upon completion of this activity, participants should be better able to: Assess recommended antifibrotic treatment for patients with ILDs; Review the rationale for novel therapy for fibrosing ILDs; and Outline multidisciplinary, patient-centered strategies to enhance care for individuals with ILDs.
Please visit answersincme.com/XWB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses combination anti–programmed cell death protein 1 (PD-1) plus anti–lymphocyte-activation gene 3 (LAG-3) therapy. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence supporting use of combination anti–PD-1 plus anti-LAG-3 therapy in the first-line setting for patients with unresectable, advanced melanoma; Identify eligible patients with unresectable, advanced melanoma who can benefit from the use of combination anti–PD-1 plus anti–LAG-3 therapy in the first-line setting; and Outline strategies for managing adverse events associated with combination anti–PD-1 plus anti–LAG-3 therapy.
Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.
Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.
Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.
Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.
Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better able to: Review guideline-recommended clinical strategies to reduce cervical cancer risk; Outline patient-focused strategies to increase acceptance of HPV vaccination across patient subpopulations; and Identify clinical approaches to enhance the uptake of recommended schedules for HPV vaccination.
Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.
Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.
Please visit answersincme.com/YZW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses biologic therapy for prurigo nodularis, and a patient presents her perspective. Upon completion of this activity, participants should be better able to: Identify the therapeutic needs of patients with PN; Review the evidence for current and emerging biologic treatments for PN; and Outline how to integrate biologic therapies into the care of patients with PN.
Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.
Please visit answersincme.com/CZY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in pediatric asthma discuss early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Identify the role of early intervention with biologics on the long-term lung function of pediatric patients with moderate to severe asthma; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate to severe asthma on lung function; and Describe evidence-based strategies for optimizing long-term lung function in pediatric patients with moderate to severe asthma. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/WMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. Upon completion of this activity, participants should be better able to: Define “clinical remission” of asthma; and Review the impact of approved biologics for the treatment of patients with T2 asthma on clinical remission; Outline strategies for incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/NVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics and immunology discusses the continued burden of respiratory syncytial virus (RSV) in infants and strategies to increase vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) prevention in infants; Review the clinical profiles of national guideline-recommended RSV prophylactic agents in infants; and Outline patient-centered strategies to optimize the uptake of RSV prophylactic options in infants.
Please visit answersincme.com/YFE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses populations at high risk for cervical cancer and how to apply clinical advances and evolve care in locally advanced disease. Upon completion of this activity, participants should be better able to: Identify populations at high risk of developing cervical cancer; Describe strategies to improve uptake of routine screening for cervical cancer, particularly in high-risk populations; and Outline clinical advances that may evolve the care of patients with newly diagnosed high-risk locally advanced cervical cancer.
Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.
Comments
Download from Google Play
Download from App Store
United States